-
Novel Cancer Therapy Phase 3 Trial Expects To Be Completed Shortly
Tuesday, April 6, 2021 - 9:07am | 912Read More...The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. As science advances in terms of finding new treatments for unmet medical needs, certain approaches are not appropriate for specific types...
-
Leerink Swann Reiterates Gilead Science (GILD) Outperform Rating
Thursday, February 18, 2010 - 10:53am | 110Read More...Leerink Swann analysts Joshua Schimmer and Steve Y. Yoo reiterated their Outperform rating of Gilead Sciences, Inc. (Nasdaq: GILD). The Leerink Swann analysts Joshua Schimmer and Steve Y. Yoo hosted a conference call with an HIV specialist who was also an investigator in the Gilead Sciences quad...
